Lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 inhibitors

被引：10
作者：
Julius U. [1 ]
Tselmin S. [1 ]
Schatz U. [1 ]
Fischer S. [1 ]
Bornstein S.R. [1 ]
机构：
[1] Lipidology and Center for Extracorporeal Treatment, Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstr. 74, Dresden
来源：
Clinical Research in Cardiology Supplements | 2019年 / 14卷 / Suppl 1期
关键词：
Cardiovascular events; LDL cholesterol; Lipoprotein apheresis; Lipoprotein(a); PCSK9; inhibitors;
D O I：
10.1007/s11789-019-00099-z
中图分类号：
学科分类号：
摘要：
Lipoprotein(a) (Lp(a)) is an internationally accepted independent atherogenic risk factor. Details about its synthesis, many aspects of composition and clearance from the bloodstream are still unknown. LDL receptor (LDLR) (and probably other receptors) play a role in the elimination of Lp(a) particles. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors increase the number of available LDLRs and in this way very effectively reduce the LDL cholesterol (LDL-C) concentrations. As shown in controlled studies using PCSK9 inhibitors, Lp(a) levels are decreased by 20 to 30%, though in some patients no effect was observed. So far, it has not been clarified whether this decrease is associated with an effect on the incidence of cardiovascular events (CVEs). In two recently published well-performed secondary prevention studies (FOURIER with evolocumab, ODYSSEY OUTCOMES with alirocumab) baseline Lp(a) levels were shown to have an impact on CVEs independently of baseline LDL-C concentrations. The rather modest PCSK9 inhibitor-induced decrease of Lp(a) was associated with a reduction of CVEs in both studies, even after adjusting (ODYSSEY OUTCOMES) for demographic variables (age, sex, race, region), baseline Lp(a), baseline LDL-C, change in LDL-C, and clinical variables (time from acute coronary syndrome, body mass index, diabetes, smoking history). The largest decrease of CVEs was seen in patients with relatively low concentrations of both LDL-C and Lp(a) (FOURIER). These findings will probably have an influence on the use of PCSK9 inhibitors in patients with high Lp(a) concentrations. © 2019, The Author(s).
引用
收藏
页码：45 / 50
页数：5
相关论文
共 22 条
[1]  
Tsimikas S., Fazio S., Ferdinand K.C., Ginsberg H.N., Koschinsky M.L., Marcovina S.M., Et al., NHLBI working group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis, J Am Coll Cardiol, 71, 2, pp. 177-192, (2018)
[2]  
Sharma M., Redpath G.M., Williams M.J., McCormick S.P., Recycling of apolipoprotein(a) after PlgRKT-mediated endocytosis of lipoprotein(a), Circ Res, 120, 7, pp. 1091-1102, (2017)
[3]  
Schulz R., Schluter K.D., PCSK9 targets important for lipid metabolism, Clin Res Cardiol Suppl, (2017)
[4]  
Reyes-Soffer G., Pavlyha M., Ngai C., Thomas T., Holleran S., Ramakrishnan R., Et al., Effects of PCSK9 inhibition with alirocumab on lipoprotein metabolism in healthy humans, Circulation, 135, 4, pp. 352-362, (2017)
[5]  
Tsimikas S., A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies, J Am Coll Cardiol, 69, 6, pp. 692-711, (2017)
[6]  
Tsimikas S., Brilakis E.S., Miller E.R., McConnell J.P., Lennon R.J., Kornman K.S., Et al., Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease, N Engl J Med, 353, 1, pp. 46-57, (2005)
[7]  
Tavori H., Christian D., Minnier J., Plubell D., Shapiro M.D., Yeang C., Et al., PCSK9 association with lipoprotein(a), Circ Res, 119, 1, pp. 29-35, (2016)
[8]  
Nave A.H., Lange K.S., Leonards C.O., Siegerink B., Doehner W., Landmesser U., Et al., Lipoprotein (a) as a risk factor for ischemic stroke: a meta-analysis, Atherosclerosis, 242, 2, pp. 496-503, (2015)
[9]  
Langsted A., Kamstrup P.R., Nordestgaard B.G., High lipoprotein(a) and high risk of mortality, Eur Heart J, (2019)
[10]  
Cao Y.X., Liu H.H., Li S., Li J.J., A Meta-analysis of the effect of PCSK9-monoclonal antibodies on circulating lipoprotein (a) levels, Am J Cardiovasc Drugs, (2018)
123